Risk factor
High price volatility
Profitability factor
Favourable analyst view
About
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of PRCT is 50 and suggests 81% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell